DANIELI, Maria Giovanna
 Distribuzione geografica
Continente #
NA - Nord America 6.619
EU - Europa 3.158
AS - Asia 2.798
SA - Sud America 699
AF - Africa 143
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
Totale 13.428
Nazione #
US - Stati Uniti d'America 6.410
SG - Singapore 905
VN - Vietnam 697
IT - Italia 626
BR - Brasile 543
RU - Federazione Russa 519
CN - Cina 438
UA - Ucraina 387
DE - Germania 297
IE - Irlanda 239
SE - Svezia 226
HK - Hong Kong 214
FR - Francia 203
FI - Finlandia 168
GB - Regno Unito 168
DK - Danimarca 138
CA - Canada 124
TR - Turchia 108
IN - India 84
KR - Corea 75
MX - Messico 63
NL - Olanda 61
AR - Argentina 52
BD - Bangladesh 52
MA - Marocco 46
CI - Costa d'Avorio 41
IQ - Iraq 38
PL - Polonia 28
PK - Pakistan 27
EC - Ecuador 24
ZA - Sudafrica 24
ID - Indonesia 22
AT - Austria 19
CO - Colombia 19
JP - Giappone 19
PH - Filippine 19
VE - Venezuela 19
BE - Belgio 17
ES - Italia 16
CL - Cile 15
UZ - Uzbekistan 14
SA - Arabia Saudita 11
TN - Tunisia 11
LT - Lituania 10
PY - Paraguay 10
TW - Taiwan 8
AU - Australia 7
IL - Israele 7
JO - Giordania 7
PE - Perù 7
IR - Iran 6
RS - Serbia 6
TH - Thailandia 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
CH - Svizzera 5
KZ - Kazakistan 5
UY - Uruguay 5
AZ - Azerbaigian 4
DZ - Algeria 4
HN - Honduras 4
MY - Malesia 4
NP - Nepal 4
DO - Repubblica Dominicana 3
ET - Etiopia 3
EU - Europa 3
GR - Grecia 3
MD - Moldavia 3
NI - Nicaragua 3
OM - Oman 3
PS - Palestinian Territory 3
RO - Romania 3
UG - Uganda 3
BH - Bahrain 2
BO - Bolivia 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
EG - Egitto 2
HU - Ungheria 2
JM - Giamaica 2
KE - Kenya 2
KW - Kuwait 2
NG - Nigeria 2
PR - Porto Rico 2
QA - Qatar 2
SR - Suriname 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
BZ - Belize 1
DM - Dominica 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
KG - Kirghizistan 1
KY - Cayman, isole 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
Totale 13.415
Città #
Ashburn 1.147
Dallas 1.028
Singapore 564
Jacksonville 390
Chandler 388
San Jose 302
Fairfield 257
Dublin 233
Boardman 229
Ho Chi Minh City 223
Hong Kong 206
Hanoi 167
New York 164
Wilmington 150
Woodbridge 144
The Dalles 133
Los Angeles 117
Beijing 114
Lauterbourg 109
Moscow 109
Munich 102
Seattle 102
Houston 101
Ann Arbor 97
Helsinki 90
Lawrence 87
Princeton 87
Des Moines 85
San Mateo 82
Cambridge 66
Montréal 62
Centro 59
Hefei 53
São Paulo 50
Mcallen 49
Ancona 45
Abidjan 41
San Diego 41
Orem 40
Council Bluffs 39
Montreal 38
Milan 36
Buffalo 34
Chicago 33
Da Nang 32
Mexico City 29
Turin 28
Santa Clara 26
Warsaw 26
Chennai 24
Washington 23
Haiphong 22
Amsterdam 19
Frankfurt am Main 17
London 17
Pune 17
Shanghai 17
Brussels 16
Guangzhou 16
Redmond 16
Tokyo 16
Baghdad 15
Stockholm 15
Florence 14
Hải Dương 14
Johannesburg 14
Rio de Janeiro 14
Tashkent 14
Wuhan 14
Atlanta 13
Manchester 13
Nuremberg 13
Boston 12
Brasília 12
Poplar 12
Saint Petersburg 12
Thái Bình 12
Brooklyn 11
Castelfidardo 11
Denver 11
Dhaka 11
Rome 11
Salvador 11
Ankara 10
Columbus 10
Curitiba 10
Lahore 10
Norwalk 10
Salt Lake City 10
Turku 10
Bologna 9
Chiaravalle 9
Phoenix 9
Belo Horizonte 8
Buenos Aires 8
Guayaquil 8
Istanbul 8
Kilburn 8
Mumbai 8
Porto Alegre 8
Totale 8.486
Nome #
Prurigo nodularis as the first manifestation of a common variable immunodeficiency 340
Insights from comparison of serum IgG4 between T2-eosinophilic asthma and eosinophilic granulomatosis with polyangiitis/idiopathic hypereosinophilic syndrome 245
Expanding the mosaic functions of intravenous immunoglobulin 237
Use of nailfold capillaroscopy for the early diagnosis of systemic sclerosis in patients with primary biliary cholangitis 215
Colonna vertebrale. Midollo spinale. Imaging 201
Clinical features and follow-up in patients with 22q11.2 deletion syndrome. 177
La scelta della maternità. Una guida alla decisione per le donne con LES 177
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITHOUT OVERT NEUROPSYCHIATRIC MANIFESTATIONS 172
A Case of CVID-Associated Inflammatory Bowel Disease with CTLA-4 Mutation Treated with Abatacept 168
IMMUNOSUPPRESSIVE THERAPY IN LUPUS NEPHRITIS: A RANDOMISED TRIAL OF LOW DOSE VERSUS HIGH DOSE INTRAVENOUS CYCLOPHOSPHAMIDE. THE EUROLUPUS NEPHRITIS TRIAL. 166
Global longitudinal strain measured by speckle tracking identifies subclinical heart involvement in patients with systemic sclerosis 164
ANCA-negative EGPA: only eosinophils without vasculitis? Insights from anti-T2 biologics 156
7th International Immunoglobulin Conference: Immunomodulation. 154
Cardiac involvement in polymyositis and dermatomyositis 151
Overexpression of the cytokine BAFF and autoimmunity risk 151
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial 148
Incidence of malignancy in patients with common variable immunodeficiency according to therapeutic delay: an Italian retrospective, monocentric cohort study 148
Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia. 147
Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. 143
The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999–2019) 143
A proteinuria cut-off level of 0.7 g /day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial 142
6th International Immunoglobulin Symposium: poster presentations. 140
The ten-year follow-up data of the Euro-lupus Nephritis Trial comparing low-dose versus high-dose intravenous cyclophosphamide. 139
Antibodies to mycobacterial 65 kDa heat shock protein in systemic sclerosis (scleroderma). 139
Autoimmune thyroid diseases in patients with undifferentiated connective tissue disease. 137
Subcutaneous IgG in the Myositis Spectrum Disorders 137
Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. 136
Serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and systemic idiopathic vasculitis. 134
Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. 133
Juvenile rheumatoid arthritis patients manifest immune reactivity to the mycobacterial 65-kDa heat shock protein, to its 180-188 peptide, and to a partially homologous peptide of the proteoglycan link protein. 133
Subclinical Cardiac Dysfunction in Polymyositis and Dermatomyositis: A Speckle-tracking Case-control Study 133
Immunohistochemical localization of intracellular and extracellular associated TGF beta in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. 132
Subcutaneous immunoglobulin in inflammatory myopathies: efficacy in different organ systems 132
Association tests with systemic lupus erythematosus (SLE) of IL10 arkers indicate a direct involvement of a CA repeat in the 5' regulatory region 131
A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases 130
The EuroMyositis registry: An international collaborative tool to facilitate myositis research 129
Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. 124
Autoimmunità, Gravidanza, Contraccezione, Terapia ormonale 123
Dr. Guerra, et al reply 123
Alarmins in autoimmune diseases 122
Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. 122
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies 122
Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. 119
Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. 118
la terapia con immunoglobuline endovena nel trattamento delle malattie autoimmuni 117
Bullous SLE: response to methotrexate and relationship with disease activity 116
Facilitated Subcutaneous Immunoglobulin (fSCIg) in Autoimmune Cytopenias Associated with Common Variable Immunodeficiency 116
Intravenous immunoglobulin as a therapy for autoimmune conditions 113
Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis 113
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. 112
Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin therapy in complicated primary antibody deficiencies 112
Common Variable Immunodeficiency in Elderly Patients: A Long-Term Clinical Experience 112
Potential Anti-Tumor Activity of Intravenous and Subcutaneous Immunoglobulin 111
Autoimmunità Gravidanza Contraccezione Terapia Ormonale 110
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. 107
Management of a pregnant woman with common variable immunodeficiency and previous reactions to intravenous IgG administration 106
Rare variants in the TREX1 gene and susceptibility to autoimmune diseases. 104
Intravenous Immunoglobulin and Mycophenolate Mofetil for Long-Standing Sensory Neuronopathy in Sjögren's Syndrome 104
Clinical Associations of Biallelic and Monoallelic TNFRSF13B Variants in Italian Primary Antibody Deficiency Syndromes 104
[Therapy of refractory rheumatoid arthritis. Cyclosporin and methotrexate combination] 103
A machine learning analysis to evaluate the outcome measures in inflammatory myopathies 103
Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial 103
Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients 103
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project 101
Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: a case-control study. 101
Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis. 101
Ultrasonographic contrast-enhanced study of sicca syndrome 99
Platelet-activating factor acetylhydrolase: A biomarker in Hymenoptera venom allergy? 98
Risk factors for Sjögren's syndrome: a case-control study. 97
Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions 96
La terapia immunosoppressiva nelle miositi refratttarie 95
Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. 95
Systemic lupus in Europe at the change of the millennium: lessons from the "Euro-lupus Project" 95
Sinchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. 94
Efficacy and safety of intravenous and subcutaneous tocilizumab in a cohort of patients affected by rheumatoid arthritis in real-life 94
Subcutaneous immunoglobulins in ocular myositis. 93
High-dose Facilitated subcutaneous Immunoglobulin in a Patient with refractory Polymyositis and severe Interstitial Lung disease 93
Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review. 91
Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. 91
Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease 91
Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations 90
Autoimmunity, COVID-19, Post-COVID19 Syndrome and COVID-19 Vaccination 89
Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus. 89
Exposome: Epigenetics and autoimmune diseases 88
Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. 87
The European Society for Immunodeficiencies (ESID) registry 2014 87
Oxidative stress, mitochondrial dysfunction, and respiratory chain enzyme defects in inflammatory myopathies 86
Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis 86
Quantitative assessment of salivary gland inflammatory infiltration in primary Sjögren's syndrome: its relationship to different demographic, clinical and serological features of the disorder. 85
The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet) 83
Hypogammaglobulinemia in patients affected by limited cutaneous systemic sclerosis: Case series and review of the literature 82
Recurrent myelitis in common variable immunodeficiency successfully managed with high-dose subcutaneous immunoglobulin. 82
Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus 82
Lessons from the "Euro-Lupus Cohort". 81
Preliminary report on the use of subcutaneous immunoglobulin in severe inflammatory myopathies 81
Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome. 80
Immunoglobulin Treatment inPolymyositis and Dermatomyositis 79
Response to: 'Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria' by Cavagnaet al 78
Polyautoimmunity Reflecting Immune Dysregulation in Common Variable Immunodeficiency 77
Valutazione obbiettiva strutturata della competenza clinica (osce) 76
Totale 12.095
Categoria #
all - tutte 56.269
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.269


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021288 0 0 0 0 0 0 0 0 0 87 134 67
2021/2022674 29 176 15 34 3 35 45 58 46 44 74 115
2022/20231.263 104 115 99 104 104 169 5 82 324 13 99 45
2023/2024915 158 40 56 123 143 188 18 34 10 32 19 94
2024/20251.759 134 170 75 31 66 94 178 91 326 158 180 256
2025/20266.444 306 878 629 654 695 448 1.140 641 536 517 0 0
Totale 13.661